Business Wire

Arctic Blue Beverages Launches New Tonic Water With a Taste of Finnish Nature – “a Good Base for All Drinks”

Share

Arctic Blue Tonic is made from the cleanest Finnish groundwater by hand in small batches in Lappeenranta, Finland.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211006005748/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Award-winning Finnish beverage company of artisan gin is launching a new tonic water. Arctic Blue Tonic combines flavours from coniferous forests with the world’s cleanest water. It is made from the cleanest Finnish groundwater by hand in small batches in Lappeenranta, Finland. (Photo: Business Wire)

“The majority of tonics on the market are quite sweet, so we wanted to create a low-sugar and low-calorie yet still tasty tonic that provides a good base for all kinds of drinks. Our starting point was to design the best tonic water in the world to go with the best gin in the world,” says Kimmo Wager, Head of Marketing at Arctic Blue Beverages.

Tonic waters usually contain as much sugar as soft drinks, even 7 to 9 grams per 100 millilitres, whereas Arctic Blue Tonic has only four grams of sugar. Arctic Blue Tonic will also be the first non-alcoholic product from Arctic Blue Beverages to be sold in grocery stores. Arctic Blue Tonic will go on sale in Finnish stores this autumn and elsewhere in Europe during 2022.

“We are also considering launching other flavoured tonic waters and different bottle sizes. In addition to our distilled products, next year we will also introduce low-alcohol products based on the best gin in the world,” Wager reveals.

Arctic Blue Gin & Tonic evokes Finnish coniferous forests

Tonic is a bitter and carbonated soft drink that is used as a mixer in many drinks. It goes especially well with gin-based drinks. Arctic Blue Tonic is designed to be the perfect pair for Arctic Blue Gin, which has been awarded as the world’s best gin.

“Arctic Blue Gin & Tonic is a unique combination of Finnish distilling expertise and the cleanest water in the world. The drink has fragrances of fresh blueberry forests and conifers. The world of flavours that the drink opens up takes you on a journey through a Finnish coniferous forest,” describes Miika Mehtiö, Brand Ambassador for Arctic Blue Beverages and World Show Bartending Champion in 2019.

Arctic Blue Gin & Tonic:

1 part Arctic Blue Gin

1 part Arctic Blue Tonic

Garnish with shrub blueberries

Billberries – the wild Arctic blueberries should be used instead of citrus fruits as a garnish to prevent the sour fruits from obscuring the refined flavours of the Finnish forest.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Further information:
Kimmo Wager
Head of Marketing
+358 400 598 545
kimmo.wager@arcticbluebeverages.com

Media contacts and test products:
Anniina Nissinen
PR and Communications Agency Mellakka Helsinki
+358 400 380010
anniina@mellakkahelsinki.fi

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye